HR for ACR 30-299 vs. <10 mg/g, 1.70 (1.45-2.00) vs. 1.34 (1.10-1.64) and 1.42 (1.10-1.85) vs. 1.57 (1.36-1.81), respectively). Only the ACR-DM interaction reached significance, with a shallower relative risk gradient among diabetics than among non-diabetics (p = 0.02). Analysis of individual cardiovascular outcomes showed similar results. Conclusion: Although individuals with DM and HTN generally had higher cardiovascular risk relative to those without these complications, both low eGFR and high ACR were associated with cardiovascular diseases regardless of the presence or absence of DM and HTN. These findings reinforce the importance of CKD in cardiovascular outcomes.
DM and HTN to kidney disease have led to recommendations for CKD screening among individuals with these conditions [9] [10] [11] [12] [13] .
DM and HTN are also important risk factors for cardiovascular diseases (CVDs) [2] [3] [4] [5] [6] [7] 14] . The risk of CVD among adults with DM is 2-4 times higher than in those without [2] . Similarly, each 20 mm Hg of higher systolic blood pressure is associated with a doubling of CVD risk [15] . CVD is also one of the most important complications of CKD [16] [17] [18] [19] . Thus, there is a complicated association between DM, HTN, CKD and CVD. However, very few studies have formally evaluated the interaction of CKD with DM and HTN on CVD outcomes.
The CKD Prognosis Consortium has reported that the association of kidney disease measures (estimated glomerular filtration rate (eGFR) and albuminuria) with cardiovascular mortality is largely similar among those with and without DM and/or HTN [14, 20] . However, mortality can be affected by healthcare system factors (e.g. availability and accessibility of care). Thus, from an etiological point of view, it is also important to investigate the interactions for incident CVD including non-fatal cases. Furthermore, since the contribution of risk factors to individual CVDs (e.g. coronary heart disease (CHD), stroke and heart failure) can vary [21] , an evaluation of each CVD subtype would be an added contribution to the existing body of knowledge.
Methods

Design and Participants
The Atherosclerosis Risk in Communities (ARIC) study is an ongoing prospective cohort study of 15,792 individuals aged 45-64 years from 4 US communities (Forsyth County, N.C.; Jackson, Miss.; Minneapolis, Minn. and Washington County, Md., USA) between 1987 and 1989 [15, 18, 19] . At the initial and 3 short-term follow-up examinations, which occurred approximately 3 years apart, trained personnel collected demographic, social, medical and physical data. Baseline characteristics of this study were taken from the fourth examination (1996-1998) which was attended by a total of 11,656 participants [22] . Of these, we excluded individuals with missing values of key exposures (eGFR and albuminuria; n = 215), key potential effect modifiers (DM and HTN; n = 92) and covariates (n = 299), leaving a final study sample of 11,050 participants.
Kidney Disease Measures
GFR was estimated from serum creatinine, age, gender and race (blacks vs. non-blacks) using the CKD Epidemiology Collaboration (CKD-EPI) equation [23] . Serum creatinine was measured using a modified kinetic Jaffé [22] and was calibrated to standardized serum creatinine by adding 0.18 mg/dl and then reducing that value by 5% [18, 24] . As recommended in clinical guidelines, urinary albumin-to-creatinine ratio (ACR) was used as a measure of albuminuria [19, 25] . Urinary albumin and urinary creatinine were measured by nephelometry and the Jaffé method, respectively.
Potential Effect Modifiers
DM was defined as self-reported physician diagnosis, use of glucose lowering medications, a fasting blood glucose level ≥ 126 mg/dl or non-fasting blood glucose level ≥ 200 mg/dl [25] . HTN was defined by a systolic blood pressure ≥ 140 mm Hg and a diastolic blood pressure ≥ 90 mm Hg or the use of antihypertensive medications. Blood pressure was determined as the average of 2 seated measurements from a random-zero sphygmomanometer [25] .
Covariates
Age, gender and race were self-reported. Height and weight were measured while the participants wore light clothing and no shoes [25] ; body mass index (BMI) was calculated as body weight (in kilograms) over height (in meters) squared. Total cholesterol levels were determined using enzymatic methods. Smoking status was categorized as current vs. ex-/non-smokers. History of CVD included a history of CHD, stroke or heart failure. A history of CHD was determined by a self-report of myocardial infarction or a coronary revascularization procedure, an adjudicated electrocardiogram evaluation of myocardial infarction at the initial visit or any adjudicated incident CHD event between the initial and fourth visits. History of stroke was similarly determined by self-report at the first examination or adjudicated cases before the fourth examination [25] . Prevalent heart failure was determined through self-reported use of heart failure medications or manifested heart failure as defined by the Gothenburg criteria at the initial examination and hospitalization for heart failure before the fourth examination [25] .
Outcome Definition
The primary outcome of interest was composite CVD, including a diagnosis of incident CHD, stroke or heart failure. Each individual CVD was separately analyzed as a secondary outcome. Information about the outcome was initially obtained using annual telephone calls, hospital records and obituaries [25] . CHD and stroke were then adjudicated by certified experts [26] . Incident CHD in this study was defined as a definite or probable myocardial infarction, definite CHD death or a revascularization procedure [25] . Incident stroke included definite and possible stroke [27] . Incident heart failure was defined as heart failure hospitalization or death due to heart failure coded as 428 or I50 according to the ICD-9 or ICD-10, respectively, on medical records or death certificates [25] .
Statistical Analysis
Baseline characteristics were compared among groups using DM and HTN status. Continuous and categorical variables were compared between the subgroups using the analysis of variance and the Chi-square tests, respectively. We defined follow-up time as the period from baseline (fourth examination) to the first outcome or loss to follow-up. Individuals who were free of the outcomes by December 31, 2009 , were administratively censored.
The Cox proportional hazards models were used to quantify the association of each kidney measure with the outcomes of interest in each subgroup by DM and HTN status. All analyses were adjusted for age, gender, race, BMI, total cholesterol level, smoking status, history of CVD, systolic blood pressure (when diabetics and non-from 30 to 105 for eGFR and knots at 10, 30 and 300 mg/g for ACR). To evaluate interaction, models with and without product terms between kidney measures and potential effect modifiers were constructed. Using the models with the product terms, we estimated the hazard ratios (HRs) for eGFR and ACR with the reference of 95 ml/ min/1.73 m 2 eGFR and 5 mg/g ACR within each subgroup. From these models, 'point-wise interaction' was evaluated as the ratio of these HRs between subgroups at each point of eGFR (1 ml/min/ 1.73 m 2 increment) and ACR (8% increment). 'Overall interaction' was tested based on a likelihood ratio test comparing the models with and without the product terms. To account for the main effect of DM and HTN on cardiovascular risk, estimates in subgroups were compared using a single reference of eGFR and ACR in reference groups (those without DM and/or HTN). We also assessed interaction for combined categories of eGFR ( ≥ 105, 90-104, 75-89, 60-74, 45-59, 30-44, 15-29 and <15 ml/min/1.73 m 2 ) and ACR (<10, 10-29, 30-299 and ≥ 300 mg/g) [14, 20] .
A p value of <0.05 (2-tailed) was considered statistically significant. All statistical analyses were performed using Stata 12 (StataCorp, College Station, Tex., USA).
Results
Participant Characteristics
A total of 5,189 (47.0%) participants had neither DM nor HTN, 628 (5.7%) had only DM, 4,022 (36.4%) had only HTN and 1,211 (11.0%) had both DM and HTN.
Participants with DM and/or HTN were more likely to be older, black, obese and have a history of CVD as compared to those without either ( table 1 ). The participants with both conditions had the highest level of systolic blood pressure, mean fasting blood glucose and prevalence of CVD. The percentage of current smokers was highest among participants without HTN and DM, and levels of total cholesterol were not substantially different across the 4 groups. During a median follow-up time of 11.7 years, there were 2,758 cases of composite CVD (1,672 cases of CHD, 558 cases of stroke and 1,375 cases of heart failure). The incidence rate of CVD was highest in participants who have both DM and HTN followed by those with only DM, those with only HTN and those without either of these conditions ( table 1 ) .
Kidney Measures, DM and CVD
With a single reference at 95 ml/min/1.73 m 2 eGFR among those without DM, individuals with DM had a higher risk of CVD relative to those without at all levels of eGFR ( fig. 1 a) . To more clearly illustrate potential differences in the contribution of kidney measures to CVD risk (potential effect modification) by the presence or absence of DM, we subsequently depicted adjusted HR according to kidney measures with separate references for those with and without DM ( fig. 1 b) . The HR of CVD according to low eGFR was generally similar among participants with and without DM at the eGFR range of 45- Overall, a similar pattern (higher relative risk according to low eGFR among those without DM compared to those with DM at eGFR <45 ml/min/1.73 m 2 ) was observed for CHD, heart failure and stroke (see online suppl. fig. 1 ; for all online suppl. material, see www.karger. com/doi/10.1159/000433450). Although overall interaction did not reach statistical significance in any of the CVD outcomes (p > 0.17), significant point-wise interaction was observed at a limited range of eGFR for CHD (32-39 ml/min/1.73 m 2 ) and stroke (17-39 ml/min/ 1.73 m 2 ), indicating a higher contribution of low eGFR to increased relative risk among those without DM compared to those with DM.
Individuals with DM had a higher risk of CVD compared to those without DM at all levels of ACR ( fig. 1 c) . With a reference of 5 mg/g ACR for both groups, CVD risk increased at ACR 10-30 mg/g among those without DM but only at ACR >30 mg/g among those with DM, resulting in a significant overall (p = 0.02) and point-wise interaction at ACR 14-110 mg/g. A less steep risk gradient according to higher ACR among the diabetic group was similarly observed for CHD and heart failure (p for overall interaction <0.05 for both outcomes), whereas the risk gradient was almost superimposed for stroke among those with and without DM (p for overall interaction = 0.9; online suppl. fig. 2 ). Table 2 presents HRs for CVD risk for 32 categories of eGFR and ACR for participants with and without DM. Although there were a few quantitative differences, CVD risk generally increased with lower eGFR and higher ACR in both groups.
Kidney Measures, HTN and CVD
While observing the main effect of HTN on CVD risk, it was found that higher HRs were generally observed across the entire range of eGFR, except at 30-45 ml/ fig. 2 a) . We also observed a decline in HRs at eGFR <30 ml/min/1.73 m 2 among those without HTN but the sample size was small in this category (4 CVD cases out of 5 participants). When separate references were set at an eGFR of 95 ml/min/1.73 m 2 among participants with and without HTN, the risk gradient was largely similar in both the groups ( fig. 2 b) . However, HRs according to low eGFR among those with HTN appeared to be higher at eGFR 60-75 ml/min/1.73 m 2 (resulting in significant point-wise interaction at a limited eGFR range) but slightly lower around an eGFR of 30-45 ml/min/1.73 m 2 as compared to those without HTN. The overall interaction was not statistically significant (p = 0.24).
Largely similar patterns were observed for CHD (online suppl. fig. 3A ) and heart failure (online suppl. fig. 3B ), although HRs for heart failure according to low eGFR were higher among those without HTN than among those at a broader eGFR range (reaching significance at eGFR 36-39 ml/min/1.73 m 2 but not overall (p = 0.28)).
We did not observe increased risk of stroke according to low eGFR among those without HTN (online suppl. fig. 3C ), although there were a small number of stroke cases in this population (6 cases out of 216 non-hypertensives with eGFR <60 ml/min/1.73 m 2 ). Higher cardiovascular risk was observed among participants with HTN than among those without at all ACR ranges ( fig. 2 c) . With a separate reference for each group, an increasing risk gradient was observed with increasing ACR among those with and without HTN, without significant point-wise or overall (p = 0.84) interaction ( fig. 2 d) .
We observed largely similar results for CHD (online suppl. fig. 4A ) and heart failure (online suppl. fig. 4B ; p for overall interaction >0.25), with a steeper risk gradient for heart failure. The risk of stroke conferred by high ACR was higher among participants with HTN at an ACR of 10-300 mg/g, with a significant point-wise interaction at 14-70 mg/g ACR. Nevertheless, the overall interaction was not significant (p = 0.17). Table 3 lists the HRs for CVD risk in 32 categories of eGFR and ACR among participants with and without HTN. CVD risk generally increased with lower eGFR and higher ACR regardless of HTN status, without a substantial difference in adjusted HR between corresponding categories for those with and without HTN.
Kidney Measures, Combination of DM and HTN, and CVD
When we analyzed 4 groups according to DM and HTN status separately, the CVD risk conferred by low eGFR increased to around eGFR 60-75 ml/min/1.73 m 2 in every group (online suppl. fig. 5 ), although the significance varied due to differences in sample size and events. Similarly, the CVD risk conferred by high ACR was largely consistent across the 4 groups and increased considerably even within the normal range (<30 mg/g), except among those with both DM and HTN. For this group, CVD risk according to high ACR increased to >ACR 30 mg/g, resulting in significant point-wise interaction at an ACR of 24-41 mg/g compared to those without either.
Discussion
As anticipated, the risk of CVD was higher in individuals with DM or HTN regardless of the level of eGFR and ACR. When we assessed the contribution of the kidney measures to CVD risk, adjusted cardiovascular risk generally increased with lower eGFR and higher ACR, regardless of the presence or absence of DM and HTN. Of note, these kidney measures were independently associated with CVD risk even among those without both DM and HTN. Our findings are largely consistent with the recent meta-analyses from the CKD-PC in reinforcing the importance of the kidney measures in health outcomes regardless of DM and HTN status [14, 20] . We have, how- ever, expanded the research on the interaction of kidney measures with DM and HTN by including non-fatal outcomes and looking at each CVD outcome separately. In our study, the only significant overall interaction on CVD was observed for ACR and DM. The CVD risk gradient according to ACR was significantly shallower in those with DM than in those without, and this pattern was consistent for CHD and heart failure, but not for stroke. The potential mechanisms for this interaction were not entirely clear. One possible explanation is the benefit of the treatment provided to people with DM. For example, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) are recommended as the first-line medication options for patients with DM and HTN [28] because of their high effectiveness at reducing CVD risk in this population [29] [30] [31] . These medications are known to reduce albuminuria, and the reduction of albuminuria after the initiation of ARB was a strong predictor of lower CVD risk among those with DM [32] . The shallowest CVD risk gradient according to high ACR was observed among those with both DM and HTN (online suppl. fig. 5B ), and those with DM were more likely to take these medications compared to those without (28.9 vs. 11.3%). One caveat to this explanation is in the fact that the prescription of angiotensin-converting enzyme inhibitors and ARB for persons with DM at ACR <30 mg/g is not common unless HTN coexists [33] . Therefore, further studies are required to confirm the ACR-DM interaction on CVD risk.
Our results emphasize the value of eGFR and albuminuria as predictors of CVD in those with and without DM and HTN. The findings for those with DM and/or HTN support screening for CKD in this high-risk population, as recommended in clinical guidelines [10] . The findings for those without either DM or HTN are particularly important since this population has been understudied in this context [14, 20] . Although the question of screening these individuals requires further assessment [9] , our results suggest that CKD be regarded as an important risk factor for CVD. This study has several limitations. First, the number of persons with only DM or both DM and HTN was small, limiting our ability to further analyze the 4 groups according to DM and HTN status. Second, reflecting the distribution in the general population [34] , the number of persons at eGFR categories 4 and 5 were small, resulting in unreliable estimates at this range in some stratified models. Third, a single measurement of eGFR and ACR was obtained, potentially leading to some degree of misclassification. Fourth, we used the CKD-EPI creatinine equation for calculation of eGFR [23, 35] , and thus confirmation of our findings with other kidney filtration markers such as cystatin C would be needed [36] . Fifth, the study participants were aged 52-75 years and were either white or black; these results may not be generalizable to individuals out of this age range and other racial/ ethnic groups. Sixth, as with any observational study, there is a possibility of residual confounding. Finally, incident heart failure was defined using the ICD code of hospitalization records and death certificates, which may underestimate the incidence of heart failure [37] .
Despite some quantitative interactions, the associations of eGFR and ACR with CVD were generally consistent among subgroups according to DM and HTN status, with significantly increased risk beyond the current thresholds of these kidney measures for CKD definition and staging in every group. These kidney measures contributed to increased CVD risk even among those without either DM or HTN. These findings emphasize the importance of kidney diseases in the development of cardiovascular outcomes, and thus the presence of CKD should warrant clinical attention regardless of DM and HTN status.
